postherpetic neuralgia pipeline insight

DelveInsight’s, “Postherpetic Neuralgia - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Postherpetic Neuralgia: Understanding

Postherpetic Neuralgia: Overview

Postherpetic neuralgia (PHN) is a common and painful complication that occurs after a shingles outbreak, caused by the reactivation of the varicella-zoster virus (VZV). It is characterized by persistent, burning or lancinating pain along a specific dermatomal pattern that lasts for months after the rash heals. The elderly and immunocompromised individuals are particularly at risk, with age and weakened immune systems being key risk factors. While prevention and early intervention are the most effective strategies, PHN remains a challenging condition to treat, often requiring multi-modal approaches to manage the pain and improve quality of life. Treatment options include anticonvulsants, antidepressants, topical agents, and nerve blocks. Despite these interventions, some patients experience significant, long-term pain. Preventive measures, such as the shingles vaccine, have proven effective in reducing the incidence of both shingles and PHN. However, once PHN develops, it can significantly impact daily functioning and mental health, necessitating ongoing management.

 

PHN primarily affects the skin area where the shingles rash occurred, often in a band around the trunk on one side of the body. Symptoms include persistent pain that lasts for three months or more after the rash has healed, which can be burning, sharp, jabbing, or deep and aching. Many individuals with PHN also experience heightened sensitivity, where even light touch, such as clothing on the skin, becomes unbearable. Additionally, some people may experience itching or numbness in the affected area. In severe cases, the pain can interfere with sleep, daily activities, and overall quality of life. PHN can also lead to psychological effects, including anxiety and depression, due to chronic pain. Early treatment and management are essential to reduce the severity and duration of symptoms.

 

The exact cause of postherpetic neuralgia (PHN) is not fully understood, but it appears to involve both peripheral and central nervous system changes. Histological studies of nerve tissue in PHN patients show damage, such as myelin and axon loss and atrophy of the dorsal horn in some cases. Research has found that patients with PHN have significantly fewer axons in affected dermatomes compared to those who experience a self-limited shingles outbreak. This suggests that structural changes in the nerves may play a role in PHN. Additionally, an unchecked inflammatory response at the neuronal level, which reduces inhibition of pain signals and promotes hypersensitivity in damaged nerves, is thought to contribute to the development of the condition. Central sensitization, where the brain and spinal cord become hyper-responsive to pain signals, is also believed to play a key role. Immune system activation and the persistence of viral particles in nerve ganglia may further perpetuate nerve damage and inflammation. Moreover, genetic factors may influence an individual's susceptibility to developing PHN. The combination of these factors leads to the chronic pain and sensory disturbances characteristic of PHN. 

 

Treatment for postherpetic neuralgia (PHN) involves prevention, early treatment of acute herpes zoster (HZ), and symptom management. Prevention includes vaccinating at-risk populations, while early treatment of HZ can reduce PHN risk. Symptom management often requires a multimodal approach, with first-line treatments including oral tricyclic antidepressants (TCAs), pregabalin, and the lidocaine 5% patch. Opioids are effective but controversial due to addiction concerns. Other options like capsaicin patches and NMDA antagonists show mixed results. Invasive treatments such as botulinum toxin, epidural injections, and spinal cord stimulation may offer relief but have variable effectiveness. Additionally, physical therapy and cognitive-behavioral therapy (CBT) can help improve patients' coping mechanisms and overall quality of life. Non-pharmacological approaches, such as acupuncture and transcutaneous electrical nerve stimulation (TENS), may also provide some symptomatic relief for certain individuals. Combining pharmacologic and non-pharmacologic treatments often yields the best results in managing PHN.

 

"Postherpetic Neuralgia- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided which includes the disease overview and Postherpetic Neuralgia treatment guidelines. The assessment part of the report embraces, in depth Postherpetic Neuralgia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postherpetic Neuralgia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Postherpetic Neuralgia R&D. The therapies under development are focused on novel approaches to treat/improve Postherpetic Neuralgia.

 

Postherpetic Neuralgia Emerging Drugs Chapters

This segment of the Postherpetic Neuralgia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Postherpetic Neuralgia Emerging Drugs

• ONO-1110: Ono Pharmaceutical Co. Ltd

ONO-1110 is an investigational drug currently undergoing development for Postherpetic Neuralgia (PHN). This drug targets the regulation of endogenous cannabinoids, distinguishing it from traditional cannabis-based treatments. While medical marijuana has been shown to provide some relief for pain and depression, it often comes with undesirable side effects such as euphoria and somnolence. ONO-1110 aims to harness the therapeutic benefits of cannabinoids without these drawbacks, offering a promising alternative for managing PHN and other diseases. The drug is undergoing clinical trials in Japan which are evaluating its potential to provide pain relief and other pharmacological benefits with fewer side effects compared to traditional cannabinoid treatments. Currently, the drug is in the Phase II stage of its development for the treatment of Postherpetic Neuralgia.

 

• UDB412: Undaunted Bio, INC

UDB412 is a repurposed drug that Undaunted Bio is reformulating into an Oral Thin Film for the treatment of pain in Trigeminal Neuralgia patients. UDB412 is being developed via the FDA’s 505(b)(2) pathway as a reformulation of the original tablet form into an oral thin film (OTF). The OTF dissolves quickly on the tongue, without the need for water, and will enable patients to take their medication even during an attack of Trigeminal Neurlagia, greatly improving the management of their pain. Currently, the drug is in Discovery stage of its development for the treatment of Postherpetic Neuralgia.

Further product details are provided in the report……..

 

Postherpetic Neuralgia: Therapeutic Assessment

This segment of the report provides insights about the different Postherpetic Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Postherpetic Neuralgia

There are approx. 3+ key companies which are developing the therapies for Postherpetic Neuralgia. The companies which have their Postherpetic Neuralgia drug candidates in the most advanced stage, i.e. Phase II include, Ono Pharmaceutical Co. Ltd.

 

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Postherpetic Neuralgia: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Postherpetic Neuralgia therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postherpetic Neuralgia drugs.

 

Postherpetic Neuralgia Report Insights

• Postherpetic Neuralgia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Postherpetic Neuralgia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postherpetic Neuralgia drugs?
• How many Postherpetic Neuralgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postherpetic Neuralgia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postherpetic Neuralgia therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Postherpetic Neuralgia and their status?
• What are the key designations that have been granted to the emerging drugs?